Sir Tony Kouzarides, FMedSci,[2] FRS[1] (born 17 January 1958) is a senior group leader at the Gurdon Institute,[5] a founding non-executive director of Abcam[6] and a Professor of Cancer Biology at the University of Cambridge.
After his studies, he joined NYU Medical Center in New York where he worked on the c-Fos oncoprotein and the characterization of the leucine zipper.
Tony Kouzarides is Professor of Cancer Biology at the University of Cambridge and a group leader at the Gurdon Institute, a research institution focused on epigenetic modifications and their involvement in cancer.
Tony is a co-founder and ex-director of Abcam plc, a publicly trading research reagents company in Cambridge, a co-founder and ex-director of Chroma Therapeutics, of a drug discovery company based in Oxford and a co-founder and current director of STORM Therapeutics, a drug discovery company based in Cambridge.
He was knighted in the 2024 King's Birthday Honours "for services to healthcare innovation and delivery".